Xeriant reported a QQ3 2024 period characterized by alarming liquidity indicators and a steeply negative profitability trajectory. The company disclosed no revenue figure for the quarter in the data provided, while cost of revenue was modest at 13,213 USD and gross profit printed as -13,213 USD, implying a negative gross margin that could reflect either a very early-stage product mix or data inconsistencies. Operating income stood at -352,960 USD, and net income was -376,327 USD, with EPS of -0.0008. On the cash-flow front, operating cash flow was -415,413 USD and free cash flow was -415,410 USD, underscoring a heavy cash burn in a period with minimal, if any, revenue recognition. The balance sheet shows total assets of 451,782 USD against total liabilities of 8,617,111 USD and negative equity of -5,314,632 USD, signaling acute balance-sheet distress and a need for external financing or equity/revenue inflection to sustain operations.
Key liquidity and leverage metrics amplify concern: current ratio and quick ratio are both reported at approximately 0.045, and the cash ratio is 0.043. Short-term debt sits at 7,476,790 USD, with net debt around 7,103,222 USD. The company carries a highly levered risk profile and a negative book value of equity, which constrains financing flexibility and increases dilution risk for shareholders if equity markets are accessed. Despite the bleak short-term picture, Xeriant remains focused on long-range aerospace technology initiatives, including hybride-electric and fully electric aircraft with VTOL capabilities and Halo, a patented VTOL drone concept. Management commentary (where available) has not been captured in the provided transcript data, limiting visibility into strategic pivots, capital plans, or potential licensing-and-royalty opportunities tied to Halo or other technologies.
Given the lack of revenue visibility and the magnitude of expenses and cash burn, the near-term investment thesis is highly contingent on external funding, successful IP monetization, and the ability to convert R&D assets into viable commercial opportunities. Investors should monitor any forthcoming guidance around funding rounds, licensing deals, or government/defense program participation that could alter the cash-flow trajectory and balance-sheet resilience.